References
- Abreu JG, Coffinier C, Larrain J, Oelgeschlager M, De Robertis EM. 2002. Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene 287:39–47
- Canel M, Serrels A, Frame MC, Brunton VG. 2013. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci 126:393–401
- Fan J, Ponferrada VG, Sato T, Vemaraju S, Fruttiger M, Gerhardt H, Ferrara N, Lang RA. 2014. Crim1 maintains retinal vascular stability during development by regulating endothelial cell VEGFA autocrine signaling. Development 141:448–459
- Glienke J, Sturz A, Menrad A, Thierauch KH. 2002. CRIM1 is involved in endothelial cell capillary formation in vitro and is expressed in blood vessels in vivo. Mech Develop 119:165–175
- Halder G, Johnson RL. 2011. Hippo signaling: Growth control and beyond. Development 138:9–22
- Harvey K, Tapon N. 2007. The Salvador-Warts-Hippo pathway – an emerging tumour-suppressor network. Nat Rev Cancer 7:182–191
- Harvey KF, Zhang X, Thomas DM. 2013. The Hippo pathway and human cancer. Nat Rev Cancer 13:246–257
- Irvine KD. 2012. Integration of intercellular signaling through the Hippo pathway. Semin Cell Dev Biol 23:812–817
- Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. 2010. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res 316:24–37
- Lim B, Park JL, Kim HJ, Park YK, Kim JH, Sohn HA, Noh SM, et al. 2014. Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancer. Carcinogenesis 35:1020–1027
- Mao Z, Ma X, Rong Y, Cui L, Wang X, Wu W, Zhang J, Jin D. 2011. Connective tissue growth factor enhances the migration of gastric cancer through downregulation of E-cadherin via the NF-κB pathway. Cancer Sci 102:104–110
- Ponferrada VG, Fan JQ, Vallance JE, Hu SY, Mamedova A, Rankin SA, Kofron M, et al. 2012. CRIM1 complexes with beta-catenin and cadherins, stabilizes cell–cell junctions and is critical for neural morphogenesis. PLoS One 7:e32635
- Rothhammer T, Braig S, Bosserhoff AK. 2008. Bone morphogenetic proteins induce expression of metalloproteinases in melanoma cells and fibroblasts. Eur J Cancer 44:2526–2534
- Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK. 2005. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65:448–456
- Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, et al. 2014. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158:171–184
- Tan TW, Lai CH, Huang CY, Yang WH, Chen HT, Hsu HC, Fong YC, Tang CH. 2009. CTGF enhances migration and MMP-13 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Biochem 107:345–356
- Umulis D, O’Connor MB, Blair SS. 2009. The extracellular regulation of bone morphogenetic protein signaling. Development 136:3715–3728
- Wilkinson L, Gilbert T, Kinna G, Ruta LA, Pennisi D, Kett M, Little MH. 2007. Crim1(KST264/KST264) mice implicate Crim1 in the regulation of vascular endothelial growth factor-A activity during glomerular vascular development. J Am Soc Nephrol 18:1697–1708
- Wilkinson L, Kolle G, Wen DY, Piper M, Scott J, Little M. 2003. CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem 278:34181–34188
- Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG. 2007. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 22:1129–1147
- Zeng H, Tang L. 2014. CRIM1, the antagonist of BMPs, is a potential risk factor of cancer. Curr Cancer Drug Targets 14:652–658
- Zhen, Y, Ye, Y, Yu, X, Mai, C, Zhou, Y, Chen, Y, Yang, H, et al. 2014. Reduced CTGF expression promotes cell growth, migration, and invasion in nasopharyngeal carcinoma. PLoS One 8:e64976